Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

MLA

Ostergaard, Mikkel, et al. Certolizumab Pegol, Abatacept, Tocilizumab or Active Conventional Treatment in Early Rheumatoid Arthritis : 48-Week Clinical and Radiographic Results of the Investigator-Initiated Randomised Controlled NORD-STAR Trial. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1428125679&authtype=sso&custid=ns315887.

APA

Ostergaard, M., van Vollenhoven, R. F., Rudin, A., Hetland, M. L., Heiberg, M. S., Nordstrom, D. C., Nurmohamed, M. T., Gudbjornsson, B., Ornbjerg, L. M., Boyesen, P., Lend, K., Horslev-Petersen, K., Uhlig, T., Sokka, T., Grondal, G., Krabbe, S., Lindqvist, J., Gjertsson, I., Glinatsi, D., … Lampa, J. (2023). Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.

Chicago

Ostergaard, Mikkel, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, et al. 2023. “Certolizumab Pegol, Abatacept, Tocilizumab or Active Conventional Treatment in Early Rheumatoid Arthritis : 48-Week Clinical and Radiographic Results of the Investigator-Initiated Randomised Controlled NORD-STAR Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1428125679&authtype=sso&custid=ns315887.